Immuno-Biological Laboratories (4570) · InitiativeDropped
Development of an 82E1 antibody-based treatment for age-related macular degeneration
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2018.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Development of an age-related macular degeneration therapy based on the 82E1 antibody and milestone agreementA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2018DroppedAnnual report
「Agreement for Monoclonal Antibody (Clone 82E1) 6 September 2017 Milestone agreement for the CONJUMAB platform to develop a humanized 82E1 antibody as a treatment for AMD (age-related macular degeneration)」
The list of terminated agreements states that the CONJUMAB milestone agreement with Intellect Neurosciences, Inc. ended on 6 September 2017. - FY2017RestatedAnnual report
「Milestone agreement for the CONJUMAB platform to develop a humanized 82E1 antibody as a treatment for AMD (age-related macular degeneration)」
The milestone agreement with Intellect concerning the AMD drug development platform is listed again in the agreement summary. - FY2016First statedAnnual report
「Milestone agreement for the CONJUMAB platform to develop a humanized 82E1 antibody as a treatment for AMD (age-related macular degeneration)」
The company changed the target disease from Alzheimer’s-type dementia to age-related macular degeneration and entered into a new milestone agreement with Intellect. The agreement term is 10 years or until the patent expires.